Filing Flows › Tango Therapeutics (TNGX) › Q4 2024
Tango Therapeutics (TNGX) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Tango Therapeutics (TNGX) reported revenue of $4.1M for the fourth quarter 2024 (Q4 2024), -24% from a year earlier and -65% from the quarter before. Operating margin was -993.7%, net loss $37.7M (915.0% of revenue).
Tango Therapeutics, Q4 2024: revenue $4.1M (-24% year over year), operating margin -993.7%, net loss $37.7M, operating cash flow −$36.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4.1M | -65% | -24% |
| Operating profit | −$40.9M | — | — |
| Net earnings | −$37.7M | — | — |
| Operating cash flow | −$36.6M | — | — |
What changed
Revenue was $4.1M in Q4 2024, down 24% year over year and down 65% from the previous quarter.
Operating costs exceeded revenue by $40.9M, an operating margin of -993.7%. Total costs grew 11% against a revenue fall of 24%. The fastest-growing cost line was General & admin (+22%). The quarter ended with a net loss of $37.7M, wider than the previous quarter's $29.2M loss.
Operating cash flow was −$36.6M. Non-cash charges added back $620K of depreciation and $7.5M of share-based compensation. Working capital and other items used $7.1M. Capital expenditures of $124K exceeded it, leaving free cash flow of −$36.8M.
Questions
What was Tango Therapeutics' revenue in the fourth quarter 2024?
Tango Therapeutics (TNGX) reported revenue of $4.1M for the fourth quarter 2024 (Q4 2024), -24% from a year earlier and -65% from the quarter before.
Was Tango Therapeutics profitable in the fourth quarter 2024?
Operating loss was $40.9M (-993.7% of revenue) and net loss $37.7M.
Source: Tango Therapeutics 10-K on SEC EDGAR.